Welcome to the e-CCO Library!

OP026: Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. Faleck1, P. Shashi2, J. Meserve3, M. Rahal4, S. Kadire4, G. Tran4, A. Weiss5, A. Winters1, S. Chablaney1, S. Aniwan6, J.L. Koliani-Pace7, G. Kochhar2, B. Boland3, S. Singh3, R. Hirten1, E. Shmidt1, K. Lasch8, M. Luo8, M. Bohm4, S. V Sagi4, M. Fischer4, D. Hudesman9, S. Chang9, D. Lukin5, K. Sultan10, A. Swaminath11, N. Gupta12, C.A. Siegel7, B. Shen2, W.J. Sandborn3, B.E. Sands1, J.-F. Colombel1, S. Kane6, E.V. Loftus6, P.S. Dulai3*

Created: Thursday, 21 February 2019, 9:14 AM
OP026: The TOPPIC Trial: a randomised, double-blind parallel-group trial of mercaptopurine versus placebo to prevent recurrence of Crohns disease following surgical resection in 240 patients
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

I. Arnott1, C. Mowat2, H. Ennis3, C. Keerie3, S. Lewis3, N. Kennedy4, A. Cahill5, A. Morris5, M. Dunlop6, S. Bloom7, J. Lindsay8, S. Subramanian9, J. Satsangi*4, TOPPIC Trial Study Group10

Created: Friday, 22 February 2019, 9:49 AM
OP026: Zero diagnostic yield of dysplasia in polyp adjacent biopsies for patients with inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lahiff C.*1, Wang L.M.2, Travis S.P.L.1, East J.E.1

Created: Wednesday, 20 February 2019, 10:36 AM
OP027: Anti-tumour necrosis factor therapy is associated with increased risk of postoperative morbidity after surgery for ileocolonic Crohns disease: outcome analysis in a prospective nationwide cohort of 592 patients conducted by the GETAID chirurgie group
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Brouquet*1, L. Maggiori2, P. Zerbib3, J. Lefèvre4, Q. Denost5, A. Germain6, E. Cotte7, L. Beyer-Berjot8, N. Munoz-Bongrand9, V. Desfourneaux10, A. Rahili11, J.-P. Duffas12, K. Pautrat13, C. Denet14, V. Bridoux15, G. Meurette16, J.-L. Faucheron17, J. Loriau18, F. Guillon19, E. Vicaut20, S. Benoist1, Y. Panis2

Created: Friday, 22 February 2019, 9:49 AM
OP027: IL-33/ST2 axis sustains gut mucosal wound healing and cancerogenesis in colitis-associated colorectal cancer
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lopetuso L.R.*1,2, De Salvo C.3, Di Martino L.3, Goodman W.3, Scaldaferri F.4, Gasbarrini A.4, Pizarro T.T.3

Created: Wednesday, 20 February 2019, 10:36 AM
OP027: SUCNR1 receptor mediates intestinal fibrosis
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Cosin-Roger1,2*, D. Ortiz-Masia2, D.C. Macias-Ceja1, L. Gisbert-Ferrandiz2, P. Salvador2, M. Hausmann3, G. Rogler3, S. Calatayud2, M.D. Barrachina2

Created: Thursday, 21 February 2019, 9:14 AM
OP028: Gut specific regulatory T cells – a new frontier for Crohn's disease therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Goldberg R.*1,2,3,4, Scotta C.3,4,5, Cooper D.6, Eliraz E.7, Nir E.7, Irving P.1,8, Sanderson J.1,8, Shpigel N.7, Marelli-Berg F.6, Lombardi G.3,4,5, Lord G.2,3,4

Created: Wednesday, 20 February 2019, 10:36 AM
OP028: Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohns disease: results from the UNITI-1 and UNITI-2 studies
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

O. J. Adedokun*1, Z. Xu1, C. Gasink1, J. Friedman1, P. Szapary1, Y. Lang1, J. Johanns1, L.-L. Gao1, Y. Miao1, H. Davis1, S. Hanauer2, B. Feagan3, W. Sandborn4

Created: Friday, 22 February 2019, 9:49 AM
OP028: Single cell RNA sequencing of t-cells in Crohn’s disease identifies tissue specific drug targets
Year: 2018
Source: ECCO '18 Vienna
Authors:

E. Festen1*, R. Weersma1, W.T. Uniken Venema1, M.D. Voskuil1, D. Graham2

Created: Thursday, 21 February 2019, 9:14 AM
OP029: Characterisation of Paneth cell dysfunction in XIAP-deficient mice
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Yabal1*, A. Wahida1, B. Popper2, K. Steiger3, P. Jost1

Created: Thursday, 21 February 2019, 9:14 AM
OP029: Drug-concentration versus symptom-driven dose adaptation of Infliximab in patients with active Crohns disease: a prospective, randomised, multicentre trial (Tailorix)
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. D’Haens*1, S. Vermeire2, G. Lambrecht3, F. Baert4, P. Bossuyt5, M. Nachury6, A. Buisson7, Y. Bouhnik8, J. Filippi9, J. vande Woude10, P. Van Hootegem11, J. Moreau12, E. Louis13, D. Franchimont14, M. De Vos15, F. Mana16, L. Peyrin-Biroulet17, H. Brixi18, M. Allez19, P. Caenepeel20, A. Aubourg21, B. Oldenburg22, M. Pierik23, A. Gils24, S. Chevret25, D. Laharie26

Created: Friday, 22 February 2019, 9:49 AM
OP029: Hypoacetylation of histone-3 is a hallmark of intestinal fibrosis in Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lewis A.*1, Felice C.1,2, Nihjuis A.1, Iqbal S.1, Mehta S.1, Feakins R.3, Armuzzi A.2, Silver A.1, Lindsay J.4

Created: Wednesday, 20 February 2019, 10:36 AM
OP02: Distinct biological profiles associated with the risk of short-term relapse and mid/long-term relapse in Crohn's disease patients stopping infliximab
Year: 2023
Source: ECCO’23 Copenhagen
Authors: PierreDr., N.(1)*;Huynh-Thu, V.A.(2);Baiwir, D.(3);Mazzucchelli, G.(4);Fléron, M.(3);Trzpiot, L.(4);Eppe, G.(4);Laharie, D.(5);Satsangi, J.(6);Colombel, J.F.(7);Hertervig, E.(8);Meuwis, M.A.(1);Louis, E.(9);
Created: Friday, 14 July 2023, 10:43 AM
OP02: The breastmilk proteomics of women with Inflammatory Bowel Disease (IBD) and its impact on fecal calprotectin and microbiota composition in their babies
Year: 2022
Source: ECCO'22
Authors: Guedelha Sabino, J.(1);Tarassishin, L.(2);Agrawal, M.(3);Eisele, C.(2);Barré, A.(2);Dubinsky, M.(4);Stone, J.(5);Nair, N.(2);Debebe, A.(2);Hawkins, K.(2);Rendon, A.(2);Hu, J.(2);Colombel, J.F.(3);Peter, I.(2);Torres, J.(6);
Created: Friday, 11 February 2022, 3:52 PM
OP02: The role of PTPN2 SNP in the pathogenesis of fibrosis in Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Li*1, J. Kuemmerle1

Created: Friday, 22 February 2019, 9:41 AM
OP02: Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study
Year: 2021
Source: ECCO'21 Virtual
Authors: Irving, P.M.(1,2);Sands, B.E.(3);Hoops, T.(4);Izanec, J.L.(4);Gao, L.L.(4);Gasink, C.(4);Greenspan, A.(4);Allez, M.(5,6);Danese, S.(7);Hanauer, S.B.(8);Jairath, V.(9,10);Kuhbacher, T.(11);Lewis, J.D.(12);Loftus Jr., E.V.(13);Mihaly, E.(14);Panaccione, R.(15);Scherl, E.(16);Shchukina, O.(17);Sandborn, W.J.(18)
Created: Wednesday, 2 June 2021, 4:12 PM
OP03 Reduced need for surgery and medical therapy after early ileocaecal resection for Crohn’s disease: Long-term follow-up of the LIR!C trial
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Stevens MD1, L. Haasnoot1, G. D’Haens1, C. Buskens2, E.J. de Groof2, E. Eshuis1, T. Gardenbroef3, B. Mol1, P. Stokkers3, W. Bemelman2, C. Ponsioen1, LIR!C

Created: Thursday, 30 January 2020, 10:12 AM
OP030: Factors associated with the first trough level of infliximab at week 2 that predicts short- and long-term outcomes in ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

T. Kobayashi*1, Y. Suzuki2, S. Motoya3, F. Hirai4, H. Ogata5, H. Ito6, N. Sato7, K. Ozaki7, M. Watanabe8, T. Hibi1

Created: Friday, 22 February 2019, 9:49 AM
OP030: Identification of disease-relevant bacterial signatures in gnotobiotic IL-10 deficient mice using fecal samples from IBD patients undergoing hematopoietic stem cell transplantation
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Metwaly A.*1, Butt L.F.1, Waldschmitt N.1, Lagkouvardos I.2, Corraliza A.M.3, Mayorgas A.3, Martinez-Medina M.4, Allez M.5, Panes J.3, Salas A.3, Haller D.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
OP030: Loss of PTPN2 in dendritic cells promotes T-cell activation and expression of co-stimulatory molecules
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Hering1*, C. Gottier1, S. Lang1, B. Becher2, G. Rogler1, M. Scharl1, M. Spalinger1

Created: Thursday, 21 February 2019, 9:14 AM